Myriad Genetics, Inc. (MYGN)
Automate Your Wheel Strategy on MYGN
With Tiblio's Option Bot, you can configure your own wheel strategy including MYGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MYGN
- Rev/Share 9.0043
- Book/Share 4.1957
- PB 1.7232
- Debt/Equity 0.3984
- CurrentRatio 1.4222
- ROIC -0.7195
- MktCap 672712653.0
- FreeCF/Share -0.5405
- PFCF -13.4543
- PE -1.6922
- Debt/Assets 0.2283
- DivYield 0
- ROE -0.6259
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | MYGN | Scotiabank | Sector Outperform | Sector Perform | -- | $6 | May 21, 2025 |
| Downgrade | MYGN | Wolfe Research | Outperform | Peer Perform | -- | -- | May 8, 2025 |
| Downgrade | MYGN | Wells Fargo | Overweight | Equal Weight | -- | $6 | May 7, 2025 |
| Downgrade | MYGN | Guggenheim | Buy | Neutral | -- | -- | April 9, 2025 |
| Upgrade | MYGN | Piper Sandler | Neutral | Overweight | $11.5 | $12.5 | March 12, 2025 |
| Initiation | MYGN | Craig Hallum | -- | Buy | -- | $29 | Feb. 12, 2025 |
| Initiation | MYGN | UBS | -- | Neutral | -- | $18 | Dec. 10, 2024 |
| Downgrade | MYGN | Leerink Partners | Outperform | Market Perform | $30 | $21 | Dec. 9, 2024 |
| Initiation | MYGN | Morgan Stanley | -- | Equal Weight | -- | $32 | Sept. 19, 2024 |
| Initiation | MYGN | Wells Fargo | -- | Overweight | -- | $35 | Aug. 28, 2024 |
News
Myriad Genetics, Inc. (MYGN) Q1 2025 Earnings Call Transcript
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Myriad Genetics, Inc. (NASDAQ:MYGN ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Matt Scalo - SVP, IR Sam Raha - President & CEO Scott Leffler - CFO Mark Verratti - COO Conference Call Participants Doug Schenkel - Wolfe Research Puneet Souda - Leerink Partners David Westenberg - Piper Sandler Tejas Sawant - Morgan Stanley Sung Ji Nam - Scotiabank Andrew Cooper - Raymond James Tycho Peterson - Jefferies Lu Li - UBS Operator Welcome to the Myriad Genetics First Quarter 2025 Financial Earnings Conference Call. [Operator Instructions] I would now like to hand the …
Read More
Myriad (MYGN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Myriad (MYGN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Myriad Genetics (MYGN) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.01 per share a year ago.
Read More
Is Myriad Genetics Stock Worth Holding in Your Portfolio Now?
Published: March 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Strategic progress and solid potential in oncology testing keep MYGN on investors' radar.
Read More
Medical Equipment Stock Jumps on Upgrade
Published: March 12, 2025 by: Schaeffers Research
Sentiment: Positive
Medical equipment stock Myriad Genetics Inc (NASDAQ:MYGN) was last seen up 9.8% at $11.25, after an upgrade from Piper Sandler to "overweight" from "neutral," with a price-target hike to $12.50 from $11.50.
Read More
Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO
Published: February 25, 2025 by: Benzinga
Sentiment: Negative
On Monday, in its earnings release, Myriad Genetics Inc. MYGN said Unitedhealth Group Inc's UNH UnitedHealthcare will stop covering multi-gene panel pharmacogenetic testing, including Myriad Genetics' GeneSight test, for its commercial, individual exchange, and certain managed Medicaid plans. This change takes effect in the first half of 2025.
Read More
MYGN Q4 Earnings Meet Estimates, Revenues Rise Y/Y, Stock Down
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Neutral
Myriad Genetics achieves strong revenue growth in the fourth quarter of 2024.
Read More
Myriad (MYGN) Reports Q4 Earnings: What Key Metrics Have to Say
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Myriad (MYGN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Myriad Genetics (MYGN) Meets Q4 Earnings Estimates
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Myriad Genetics (MYGN) came out with quarterly earnings of $0.03 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.04 per share a year ago.
Read More
About Myriad Genetics, Inc. (MYGN)
- IPO Date 1995-10-06
- Website https://myriad.com
- Industry Medical - Diagnostics & Research
- CEO Samraat S. Raha
- Employees 2700